October 22, 2014 | --
AstraZeneca (NASDAQ: AZN) today announced that its European rights to its generic version of Nexium have been granted by a European regulator to Teva Pharmaceutical Industries Ltd. (NYSE: TEV).
AstraZeneca’s patent for the drug, Nexium 24HR, expires in 2023, and Teva Pharmaceuticals Industries Ltd. (NYSE: TEV) has entered into a marketing agreement with AstraZeneca to launch the generic version of Nexium on October 21, 2014. The European patent is currently set to expire in 2023.
AstraZeneca has a long history of successfully marketing its generic versions of Nexium and Prilosec. Its Nexium product, developed in a Phase III trial conducted in the early 2000s, was approved by the U. S. Food and Drug Administration in 2003 and has been sold worldwide since then. In 2011, AstraZeneca sold Nexium and Prilosec on a global scale to more than 150 countries.
The European patent for Nexium, known generically as esomeprazole, expires in 2023, and Teva Pharmaceuticals Industries Ltd. (NYSE: TEV) has entered into a marketing agreement with AstraZeneca to launch the generic version of esomeprazole on October 21, 2014. The U. patent is currently set to expire in 2023.
AstraZeneca’s Nexium product, developed in a Phase III trial conducted in the early 2000s, was approved by the U.
As part of this agreement, Teva Pharmaceuticals Industries Ltd. will continue to manufacture and market its generic versions of esomeprazole, Nexium and Prilosec. The generic version of esomeprazole will be launched in Europe in the second quarter of 2014, and the U. generic version in the first quarter of 2015. The generic version of esomeprazole will also be launched in the U. in the second quarter of 2015.
For more information on Nexium and Esomeprazole, see the
.
AstraZeneca’s rights to Nexium, a generic version of esomeprazole, have been granted by a European regulator to Teva Pharmaceutical Industries Ltd. (NYSE: TEV) by which it will have exclusive rights to enter into a marketing agreement with AstraZeneca. Teva Pharmaceuticals Industries Ltd. has entered into a marketing agreement with AstraZeneca to launch the generic version of esomeprazole on October 21, 2014.
The European patent for Nexium will expire in 2023. AstraZeneca has entered into a marketing agreement with Teva Pharmaceuticals Industries Ltd. to market its generic version of esomeprazole, in both the U. and other countries.
AstraZeneca’s rights to Nexium will be subject to final regulatory approval in Europe by the European Medicines Agency. For more information, visit www.astrazeneca.com.
This article and its accompanying headlines will be updated as new information becomes available. All trademarks and brands are the property of their respective owners.
Copyright © 2025 American Society of Health-System Pharmacists, LLC. All rights reserved.
Content © 2025 Society for the New Media. Updated for subscribers on this site: 2025-12-04SUNclosure of all rights.
The information in this notice is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, side effects, adverse drug effects, drug-drug or vaccine interactions or adverse drug effects.
This notice is provided as a courtesy. You may for your personal use, but none of this notice is sold or transmitted to otherens in any form without a registered statement of authorship from your own.
1-Century Pharmaceuticals Inc. © 2025 Society for the New Media.
3-Ajanta Pharmaceuticals, Inc.Walgreens has teamed up with, a leading online retailer to raise $1 billion in Series A and Series B funding for the manufacturer and its partner,.
The company announced that it has raised $1 billion from its shareholders, with Series A funding the maker of Nexium (esomeprazole) and AstraZeneca’s (omeprazole) generic. Other Series A funding includes the company’s $15 million Series B round of $1.7 billion.
Nexium is a prescription painkiller used to treat gastroesophageal reflux disease (GERD), a condition in which the stomach or esophagus breaks down. It is used to treat chronic conditions such as to prevent regurgitation of food or other contents of the esophagus, such as milk and yogurt, caused by GERD.
Walgreens is the first of a $2 billion Series B round of $1.7 billion and is being led by the company’s former vice president of global marketing, Jeffrey Kindler. Kindler is expected to replace Walgreens Chief Executive Officer Bill McKillop in the second quarter.
The company also announced that its second-quarter net loss in the quarter was $3.4 billion. That comes as Walgreens’s earnings per share was up 3% to $2.17, a 2.9% jump from the year prior.
Nexium, which was introduced in September, has been a hit in the U. S. since then. The patent for Nexium was set to expire on May 13, 2012, but a number of generic versions of the drug are also available. Walgreens has received final approval from the U. Food and Drug Administration (FDA) for a generic version of the drug.
“The Nexium brand was a game-changer for us in the early years of the drug’s existence,” said Les Funtleyder, an analyst at New York-based W. W. McNeil Research.
Walgreens expects Nexium to remain on the market at the current price. It expects that price to stay stable at $1 per tablet in the first two years of the patent expiry. The company expects a number of generic versions of the drug to reach the market within the next few years.
The company is working on a new marketing strategy to increase sales of Nexium and AstraZeneca’s generic drug, omeprazole. Omeprazole is a stomach-inhibiting drug that is used to treat gastroesophageal reflux disease (GERD) and is also used to treat pain and inflammation caused by GERD. The U. patent for omeprazole expires on June 17, 2012.
Walgreens also has a plan to bring its product, known as Nexium’s new name, to the U. market. The company is looking for a new product to be developed that is identical to the brand name version. Omeprazole, the brand name for omeprazole, will be developed by AstraZeneca.
Walgreens and AstraZeneca have both been awarded the rights to Nexium and the brand omeprazole. Omeprazole is approved for gastroesophageal reflux disease treatment in the U. and Europe. Nexium is also being approved in the U. and Europe and AstraZeneca’s generic omeprazole will be developed by AstraZeneca.
Nexium is a prescription drug that was approved by the U. Food and Drug Administration (FDA) in 1995. The brand version is also available in the U. Omeprazole is also approved in the U.
The company’s other key products include Prilosec, Nexium’s generic version, and its generic omeprazole.
Related article:
References:
www.walgreens.com/news-releases/walgreens-filed-in-US-EU-2013/news-releases-walgreens-filed-in-us-2013.htmlwww.walgreens.The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.
Lasting relief for frequent heartburn and acid reflux.
Always read the label and follow the directions for use.
Nexium 24HR 20 mg enteric coated tablets for the lasting symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux.
Always take this medicine exactly as described in the Consumer Medicine Information leaflet or as your doctor or pharmacist have told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is one tablet a day. - Do not take more than this recommended dose of one tablet (20 mg) a day, even if you don't feel an improvement immediately. - You may need to take Nexium 24HR for a few days before experiencing the full effect. - Nexium 24HR should be taken for at least 7 days and up to 14 days. - Tell your pharmacist or doctor if you do not feel better while taking Nexium 24HR. If symptoms persist or recur within 2 weeks of completing the course, consult your doctor. Further examination may be required.
Always read the label, use only as directed. Tell your pharmacist or doctor if you notice any of the following and they worry you: nausea or vomiting, constipation, diarrhoea, headache, wind, stomach pain, skin rash, itchy skin, dizziness or dry mouth. These side effects are usually mild. Tell your pharmacist or doctor if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop. Some medicines may interfere with Nexium 24HR. Do not take Nexium 24HR if you are pregnant unless your doctor says so. Ask your doctor about the risks and benefits involved. It is not known if it is safe for you to take Nexium 24HR while you are pregnant. It may affect your baby. Do not take Nexium 24HR if you are breastfeeding. Ask your doctor for more information. It is not known if Nexium 24HR is excreted in breastmilk if you are breastfeeding.
intactburnAsk your doctor or pharmacist for if you need to or will be breast-feeding, especially if you are breast-feeding for a long time. You may need to take Nexium 24HR once a day for a few days before experiencing the full effect. Keep all your doctor and pharmacist appointments. Do you hear chest or muscle ache or feel sore for more than 2 days? Please call your doctor if you experience any of these symptoms or if you have any further questions.
acidAcid is a common side effect of Nexium 24HR. This side effect usually goes away after a few days. Do not take Nexium 24HR if you are taking riociguat (Adempas) or nitrates as needed. Your doctor will decide what treatment is best for you. Ask your doctor or pharmacist for the EMAga list of antibiotics.
The nexium market is a significant segment of the pharmaceutical industry, driven by its efficacy, safety, and ease of administration characteristics. OTC products like NEXIUM 20mg, esomeprazole magnesium NEXIUM 20mg, and Prilosec NEXIUM 20mg are significant segments due to their convenience, efficacy, side effects, and widespread use.
The global nexium market is expected to experience significant growth over the coming years. As of 2023, the market size was valued at USD 2.59 billion and is projected to reach USD 4.61 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.deGains compared to the following years. As of 2023, the market size was valued at USD 9.89 billion and is expected to grow at a CAGR of 6.5% from 2024 to 2031[1][4].
The increasing prevalence of chronic diseases is a major driver of the nexium market. By the end of 2023, the market is expected to grow at a CAGR of 4.0% from 2024 to 2031, driven by several key factors:
One of the major restraint's the increasing prevalence of chronic diseases is the demand for innovative new therapies and effective treatments, as well as the increasing preference for medicines with fewer side effects. The presence of rare diseases brands and the frequent use of nexium products by patients are also expected to reduce the risk of side effects associated with these diseases, which is expected to remain high during the market'y years[3].
The cost of NEXIUM 20mg and Prilosec NEXIUM 20mg is expected to remain competitive, with an average cost per pill expected to increase by between $1 and $4. The cost of NEXIUM 20mg, esomeprazole magnesium NEXIUM 20mg, and the cost of Prilosec NEXIUM 20mg, itchy Ehrlich cysts (an esophagitis) expected to reach $6.60 and $4.15 during the same period, respectively. The absence of specific cost-saving applications in the nexium market due to these restrainteases the share growth due to these products' widespread use[3].
Q: What is the current market size, number ofrazeneca stockhool generic nexium HYDROCHLORIDE, and price range for the generic version?A: The market size was valued at USD 2.59 billion in 2024 and is projected to grow at a CAGR of 4.0% during the same years[1].
Q: What is the price range for the generic version of Nexium 20mg?A: The generic version of Nexium 20mg is available without a prescriptione[1].
Stade de France Pharmacy